Hwa Shan Announces Collaboration Agreement with Taiwan Tanabe Seiyaku for Co-Development of Diabetic Foot Ulcer Treatment

Disclosure Date: 1150807 Statement Date: 1150806 Statement Time: 153733 Company Code: 6657 Company Name: Hwa Shan Subject: Announcement of the execution of a co-development agreement with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Tanabe Mitsubishi Pharma in Taiwan. Applicable Clause: Clause 10 Event Date: 1150806 Details: 1. Event Date: 115/08/06 2. Counterparty to the Contract or Commitment: Taiwan Tanabe Seiyaku Co., Ltd. 3. Relationship with the Company: None 4. Contract or Commitment Period (or Termination Date): 115/08/06 ~ 117/11/30 5. Main Content (Not applicable if terminated): The Company has signed a co-development agreement with Taiwan Tanabe Seiyaku Co., Ltd. (hereinafter referred to as 'Tanabe Seiyaku') to jointly develop ENERGI-F703DFU for the treatment of diabetic foot ulcers. The Company will provide technical documents to Tanabe Seiyaku to facilitate technology transfer. 6. Restrictive Clauses (Not applicable if terminated): As stipulated in the contract. 7. Commitments (Not applicable if terminated): As stipulated in the contract. 8. Other Important Agreed Matters (Not applicable if terminated): As stipulated in the contract. 9. Impact on the Company's Financial and Business Operations: According to the terms of the co-development agreement and by mutual agreement, the financial amount of the contract will not be disclosed. However, related amounts will be recognized and disclosed in future financial reports as required. 10. Specific Purpose: The collaboration is expected to accelerate the sales of F703DFU in Taiwan following its approval by regulatory authorities. 11. Other Matters to be Disclosed (If the entity involved in the event or resolution is a publicly listed company or above, this material information also qualifies as a matter under Article 7, Paragraph 8 of the Enforcement Rules of the Securities Trading Act that significantly affects shareholders' rights or securities prices): New drug development involves long timelines, high investment costs, and no guarantee of success, which may pose investment risks. Investors should carefully assess and prudently invest.